2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Neoplasms
19
Endometrial Neoplasms
15
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Breast Neoplasms
5
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Colonic Neoplasms
4
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Locally Advanced Rectal Cancer (LARC)
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
dostarlimab
×
Clear all
NCT03981796
2025-09-03
RUBY
Tesaro, Inc.
Phase 3
Active not recruiting
785 enrolled
2 FDA
NCT05855811
2024-07-15
PREDOSTAR
Centre Leon Berard
Phase 2
Recruiting
400 enrolled